Management of Adverse Events With Alpelisib Plus Fulvestrant in Patients With HR+ Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer
Ann. Oncol 2020 May 13;[EPub Ahead of Print], HS Rugo, F André, T Yamashita, H Cerda, I Toledano, SM Stemmer, JC Jurado, D Juric, I Mayer, EM Ciruelos, H Iwata, P Conte, M Campone, C Wilke, D Mills, A Lteif, M Miller, F Gaudenzi, S LoiblFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.